On May 21, 2026‌, Hasten Biopharmaceutical Co., Ltd. (hereinafter "Hasten") once again made the "China Future Healthcare Rankings 2026-Top 100 Innovative Biopharmaceutical Companies" list, being announced at the "2026 VBEF Future Healthcare & Pharma Top 100 Awards Ceremony", a renowned healthcare industry ceremony hosted annually since 2015 by VCBeat Health.

As a start-up in the biopharmaceutical industry, being listed for the second consecutive year not only highlights our continuous drive for self-breakthrough, but also reflects broad industry recognition of Hasten's ‌core strength‌.

‌Hasten has long been focusing and enhancing its MAH integrated management capacities. Efforts never fail the aspiring‌. In October, 2024, Hasten has completed the Marketing Authorization Holder (MAH) transfer of ‌Stilamin^®‌ in mainland China, Hong Kong S.A.R., Taiwan, Province of China and Switzerland‌. ‌In ‌Jan., 2025‌, Hasten completed the MAH transfer of ‌Basen^®‌ in mainland China; In ‌Jun., 2025‌, we completed the MAH transfer of ‌Rocephin^®‌ in mainland China; In ‌Nov., 2025‌, we witnessed ‌70 ‌MAT for the Asia-Pacific product portfolio.

This rapid execution of multi-products, multi-region MAH transfers demonstrate Hasten's comprehensive strength in regulatory compliance, supply chain and quality management, and commercial operations—aligning with international standards and forming a solid foundation for its future growth.